Investors Buy Large Volume of Call Options on Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) saw some unusual options trading on Thursday. Stock investors acquired 4,046 call options on the stock. This is an increase of approximately 74% compared to the average daily volume of 2,321 call options.

Sanofi Stock Performance

SNY stock opened at $42.89 on Friday. The stock has a 50-day moving average price of $43.46 and a 200-day moving average price of $45.22. Sanofi has a 1-year low of $40.89 and a 1-year high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The firm has a market cap of $103.98 billion, a PE ratio of 11.98, a price-to-earnings-growth ratio of 1.13 and a beta of 0.34.

Wall Street Analyst Weigh In

A number of research firms recently commented on SNY. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Finally, Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $49.50.

Key Headlines Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter adjusted earnings of $1.19 per share, ahead of the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, exceeding expectations. Sanofi quarterly earnings report
• Positive Sentiment: Sales of Dupixent, Sanofi’s key asthma and immunology drug, continued to drive growth and reportedly surpassed €5 billion for the quarter for the first time. The strength prompted Sanofi to raise its 2026 outlook, calling for approximately 10% sales growth excluding currency effects, with business earnings per share expected to grow slightly faster. Reuters Sanofi sales outlook article
• Neutral Sentiment: Unusual options activity saw traders purchase about 4,046 call options, roughly 74% above typical daily call volume. This indicates increased speculative interest but does not establish a clear direction for the stock.
• Negative Sentiment: Despite the earnings beat, investors focused on setbacks in Sanofi’s pipeline and concerns about weak decision-making in research and development. New CEO Belen Garijo said the company would pursue a more disciplined R&D strategy and work to rebuild its drug-development engine, highlighting execution risks and the need for future pipeline successes. Sanofi R&D strategy article

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after buying an additional 940,342 shares in the last quarter. Morgan Stanley grew its position in shares of Sanofi by 20.4% during the 4th quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after buying an additional 1,540,271 shares during the period. Invesco Ltd. increased its stake in shares of Sanofi by 5.4% in the 4th quarter. Invesco Ltd. now owns 6,110,874 shares of the company’s stock valued at $296,133,000 after acquiring an additional 313,327 shares in the last quarter. Raymond James Financial Inc. increased its stake in shares of Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Sanofi by 29.7% during the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after acquiring an additional 1,168,339 shares during the period. 14.03% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.